Full-Time

Biostatistician

Confirmed live in the last 24 hours

Medpace, Inc.

Medpace, Inc.

1,001-5,000 employees

No salary listed

Senior, Expert

London, UK + 1 more

More locations: Stirling, UK

Office-based position in Central London or Stirling.

Category
Biology Lab & Research
Biology & Biotech
Required Skills
SAS
Data Analysis
Requirements
  • Ph.D. degree in Biostatistics / Statistics / Medical Statistics
  • Experience in SAS Programming
  • Knowledge of advanced statistical methods and knowledge of the pharmaceutical industry
  • Knowledge of regulatory requirements/guidelines for drug development
Responsibilities
  • Contribute to clinical development of plan preparation
  • Review of study protocol and preparation of statistical methodologies
  • Development of detailed Data Analysis Plan for assigned projects
  • Programming of study analysis, review of study results and preparation of statistical methods section for clinical / statistical reports
  • Communicate project requirements for CRF design, database design and database clean-up to ensure the key study variables are suitable for analysis
  • Communicate statistical results to medical writing personnel to ensure accurate interpretation.
Desired Qualifications
  • Previous experience in a pharmaceutical or CRO preferred

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Irving, Texas

Founded

1992

Simplify Jobs

Simplify's Take

What believers are saying

  • Significant revenue growth in Q4 2023 indicates strong market demand and effective strategies.
  • Recent investments by financial institutions reflect confidence in Medpace's growth potential.
  • Expansion of medical leadership team suggests increased focus on clinical research and development.

What critics are saying

  • Increased competition from Lantheus and others may pressure Medpace's market share.
  • New Cincinnati office construction could lead to higher operational costs and project delays.
  • Decreased net income margin in 2023 indicates challenges in maintaining profitability.

What makes Medpace, Inc. unique

  • Medpace's expansion in infectious diseases and vaccines shows strategic focus on high-demand sectors.
  • New leadership in respiratory and women's health enhances Medpace's expertise and service offerings.
  • Commitment to infrastructure growth with new Cincinnati office supports future operational efficiency.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Flexible Work Hours

Unlimited Paid Time Off

Competitive Compensation and Benefits Package

Employee Health and Wellness Initiatives

Hybrid Work Options

Structured Career Paths with Opportunities for Professional Growth

Company News

Financial Modeling Prep
Feb 28th, 2025
Lantheus Holdings, Inc. (NASDAQ:LNTH) Demonstrates Strong Capital Efficiency

Lantheus competes with other companies in the medical and pharmaceutical industries, such as ShockWave Medical, Medpace Holdings, LivaNova, Apellis Pharmaceuticals, and Natera.

Stock Titan
Aug 15th, 2024
Skanska builds new office building in Cincinnati, Ohio, USA, for USD 164M, about SEK 1.7 billion

STOCKHOLM, Aug. 15, 2024 /PRNewswire/ - Skanska has signed a contract with Medpace, a clinical research company, for the construction of a new office building in Cincinnati, Ohio, USA.

MarketBeat
Apr 8th, 2024
First National Bank of Hutchinson Invests $786,000 in Medpace Holdings, Inc. (NASDAQ:MEDP)

First National Bank of Hutchinson invests $786,000 in Medpace Holdings, Inc. (NASDAQ:MEDP).

PharmiWeb
Feb 13th, 2024
Medpace Holdings, Inc. Reports Fourth Quarter And Full Year 2023 Results

Revenue of $498.4 million in the fourth quarter of 2023 increased 26.5% from revenue of $394.1 million for the comparable prior-year period, representing a backlog conversion rate of 18.5%.Net new business awards were $614.7 million in the fourth quarter of 2023, representing an increase of 26.7% from net new business awards of $485.1 million for the comparable prior-year period, which resulted in a net book-to-bill ratio of 1.23x.Fourth quarter of 2023 GAAP net income was $78.3 million, or $2.46 per diluted share, versus GAAP net income of $68.7 million, or $2.12 per diluted share, for the comparable prior-year period. Net income margin was 15.7% and 17.4% for the fourth quarter of 2023 and 2022, respectively.EBITDA was $95.8 million for the fourth quarter of 2023, an increase of 19.2% from EBITDA of $80.4 million for the comparable prior-year period, resulting in an EBITDA margin of 19.2%. CINCINNATI--(BUSINESS WIRE)--Medpace Holdings, Inc. (Nasdaq: MEDP) (“Medpace”) today announced financial results for the fourth quarter and full year ended December 31, 2023. Fourth Quarter 2023 Financial Results

MarketBeat
Feb 2nd, 2024
Hussman Strategic Advisors Inc. Invests $1.02 Million in Medpace Holdings, Inc. (NASDAQ:MEDP)

Hussman Strategic Advisors Inc. invests $1.02 million in Medpace Holdings, Inc. (NASDAQ:MEDP).